| Study | Sample Size | Tumor Type | Duration of Follow-Up | Number (%) with Radiation Retinopathy at End of Follow-Up | Predictors of Radiation Retinopathy after Treatment |
| Sagoo et al. 2007 [10] | 37 patients | Circumpapillary choroidal melanoma | Mean 52 months, median 46 months | 7/37 (18.9%) with proliferative retinopathy | -- |
| Sagoo et al. 2008 [11] | 141 patients | Juxtapapillary choroidal melanoma overhanging optic disc | Mean 56 months | 61 (43.3%) patients with nonproliferative retinopathy, 26 patients (18.4%) progressed to proliferative retinopathy by the end of follow-up | -- |
| Correa et al. 2009 [41] | 120 patients | Choroidal melanoma treated with iodine-125 brachytherapy | -- | 7.5% with retinopathy | -- |
| Bianciotto et al. 2010 [42] | 3841 patients | Choroidal melanoma | -- | 138/3841 (3.6%) with proliferative retinopathy | Young age, diabetes mellitus, shorter tumor distance to optic disc |
| Finger et al. 2010 [30] | 384 patients | Uveal melanomas treated with Palladium-103 | Mean 47.2 months | Maculopathy in 8% of patients with anterior tumor and 41% of patients with posterior tumor | Posterior location, tumor height > 6.0 mm |
| Verschueren et al. 2010 [13] | 430 patients | Choroidal melanoma | Median 50 months | 56/430 (13.0%) with retinopathy; 65/430 (15.1%) with maculopathy | -- |
| Newman et al. 2011 [15] | 50 patients | Subfoveal choroidal melanomas with ≥6 months of follow-up | Median 54 months | 28/50 (56%) with retinopathy; Stage 1: None; Stage 2: 14%; Stage 3: 54%; Stage 4: 32% | -- |
| Finger et al. 2012 [16] | 24 patients | Choroidal melanomas within 1.5 mm of optic disc treated with slotted radiotherapy | Mean 23 months | 9/24 (37.5%) with maculopathy | -- |
| Berry et al. 2013 [17] | 82 patients | Medium sized choroidal melanomas | Median 46.8 months | 31/82 (37.8%) with retinopathy | -- |
| Krema et al. 2013 [38] | 30 patients | Posterior tumor margin 0 - 2.5 mm from optic disc | -- | 60% with retinopathy | -- |
| Semenova et al. 2013 [19] | 72 patients | Small choroidal melanomas | Mean 54 months | 31/72 (43.1%) with maculopathy | -- |
| Sagoo et al. 2014 [32] | 650 eyes | Juxtapapillary choroidal melanoma | Median 40 months | Nonproliferative retinopathy at 5 years: 66%; Proliferative retinopathy at 5 years: 24%; Maculopathy at 5 years: 56% | Nonproliferative: Hypertension; Proliferative: Mean tumor thickness; Maculopathy: Visual acuity > 20/60 at presentation |
| Semenova et al. 2014 [20] | 47 patients | T3 or T4 sized choroidal melanomas treated with palladium brachytherapy | Median 47 months | 31/47 (66%) with retinopathy | -- |